Caplin Point Laboratories Ltd (CAPLIPOINT)
₹2,325.60
Mkt cap
₹17,677 Cr
P/E ratio
26.60
P/B
5.25
Div yield
0.34%
ROE
20.90%
ROCE
24.20%
EPS (TTM)
₹87.43
Book value
₹443
52W range
1,500–2,990
Sector
Healthcare
Price history
Previous close
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. [1]
NSE CAPLIPOINTBSE 524742
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−22.22% from high₹2,326
₹1,500+55.01% from low₹2,990
Current
₹2,325.60
Prev close
₹2,376.10
Day
−2.13%
Price performance
1D
−1.90%
1W
+4.91%
1M
−15.05%
3M
−8.09%
6M
+34.93%
1Y
+15.22%
YTD
+25.79%
Financials
Revenue, profit & margin
P/E ratio
26.6×
CAPLIPOINT is 22% below the sector median of 34.0×
CAPLIPOINT26.6×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 | |
| Expenses | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 | |
| Operating Profit | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 | |
| OPM % | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% | |
| Other Income | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 | |
| Profit before tax | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 | |
| Tax % | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% | |
| Net Profit | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 | |
| EPS in Rs | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 | 23.27 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.13% · closed higher next day 19 of last 40
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23 | 9 Feb '24 | 17 May '24 | 7 Aug '24◦ | 8 Nov '24 | 7 Feb '25◦ | 15 May '25◦ | 7 Aug '25◦ | 5 Nov '25◦ | 5 Feb '26 | 14 May '26 | 12 Aug '26 |
| Earnings day | +8.36% | −0.77% | −1.65% | −6.27% | −5.18% | −4.38% | +0.47% | +2.56% | +0.46% | −0.29% | +9.88% | −5.98% |
| +1 day | +14.06% | +2.88% | −3.58% | −5.07% | −5.16% | −8.15% | +8.02% | +2.40% | −3.14% | −4.39% | +8.52% | −4.94% |
| +5 days | +14.75% | +9.20% | −4.43% | +0.30% | −6.27% | −10.38% | +9.61% | +4.54% | −2.95% | −9.04% | +10.00% | −2.23% |
| +15 days | +12.97% | +6.05% | +0.13% | +20.51% | +8.99% | −18.37% | +4.63% | +3.36% | −4.34% | −9.47% | +10.39% | +3.46% |
| +30 days | +25.81% | −12.76% | +6.49% | +22.70% | +12.98% | −10.22% | +4.17% | +9.49% | −4.39% | −15.99% | +38.88% | +9.04% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Rs 4 Per Share | 4.00 | 29 May '26 | 30 May '26 |
Shareholding
as of Sep 202670.57%Promoter
Promoters70.57%
FIIs5.72%0.04
DIIs2.20%0.29
Public21.52%0.33
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Caplin Point Lab | ₹2,325.60 | 26.57 | 17,677 | 0.34% | 179 | +15.78% | 610 | +19.63% | 24.24% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts52
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Regulation 74(5) compliance certificate for quarter and half year ended September 30, 2026.Closure of Trading Window 28 SepShareholder Meeting / Postal Ballot-Scrutinizer''s Report 25 SepShareholder Meeting / Postal Ballot-Outcome of AGM 25 SepClarification With Respect To Volume Movement 25 Sep - Company says recent share volume spike is market-driven and no material information is withheld.